Avaxia has developed a proprietary technology platform to produce Avaximabs™. The design of Avaximabs™ is leverages years of Avaxia’s work with milk-derived bovine polyclonal antibodies, which have been engineered by nature to resist digestion in the gastrointestinal tract.
Antibodies are a proven class of drug products, with sales approaching $100 billion per year across many different therapeutic areas. However, traditional antibody drugs cannot be delivered to the gastrointestinal (GI) tract (i.e., the mouth, throat, and intestines) because they are susceptible to digestion and are rapidly degraded. Consequently, these antibodies are administered by injection or infusion with applications in treating systemic diseases. In contrast, Avaximabs are administered orally and can access the GI tract due to their unique digestion resistance. This enables Avaxia to treat GI-related diseases in an entirely new way, with the potential for improved efficacy, safety, and convenience.